An Oncologist’s Experience With Treating R/R B-ALL With Brexucabtagene Autoleucel in Clinical Practice


Dr Jae Park shares his experience with using brexucabtagene autoleucel for patients with relapsed/refractory B-cell acute lymphoblastic leukemia in clinical practice since its FDA approval in October 2021.

Related Videos
Expert on ovarian cancer
Expert on ovarian cancer
Related Content